Content about Dipeptidyl peptidase-4 inhibitors

April 19, 2013
FDA grants tentative approval to two Sun generics

The Food and Drug Administration has given tentative approval to two generic diabetes drugs made by Sun Pharmaceutical Industries, the Indian drug maker said.

MUMBAI, India — The Food and Drug Administration has given tentative approval to two generic diabetes drugs made by Sun Pharmaceutical Industries, the Indian drug maker said.

Sun announced the tentative approvals for sitagliptin tablets in the 25 mg, 50 mg and 100 mg strengths and metformin hydrochloride extended-release tablets in the 500 mg and 1,000 mg strengths. The drugs are respectively generic versions of Merck's Januvia and Santarus' Glumetza.

January 28, 2013
FDA approves three new drugs for Type 2 diabetes

The Food and Drug Administration has approved three new drugs for Type 2 diabetes made by Takeda, the agency said.

SILVER SPRING, Md. — The Food and Drug Administration has approved three new drugs for Type 2 diabetes made by Takeda, the agency said Friday.

The FDA announced the approval of Nesina (alogliptin), Kazano (alogliptin and metformin) and Oseni (alogliptin and pioglitazone) tablets.

Alogliptin is a new active ingredient, while metformin and pioglitazone are drugs already on the market.

June 20, 2011
Q&A: A new drug for Type 2 diabetes — Wa'el Hashad, Boehringer Ingelheim

Last month, the Food and Drug Administration approved Tradjenta (linagliptin), an oral Type 2 diabetes drug made by German drug maker Boehringer Ingelheim and Indianapolis-based Eli Lilly. The drug belongs to the class known as dipeptidyl peptidase-4 inhibitors, which also includes Merck’s Januvia (sitagliptin). With diabetes affecting some 26 million Americans and growing rapidly, Drug Store News spoke with Wa’el Hashad, BI’s VP cardiovascular and metabolic disorders marketing, about what the approval of Tradjenta means for the diabetes market.


April 15, 2011
PhRMA honors scientists that helped discover Januvia

The main trade group representing branded drug makers gave an award to two Merck scientists who helped discover an oral medication for Type 2 diabetes.

JERSEY CITY, N.J. — The main trade group representing branded drug makers gave an award to two Merck scientists who helped discover an oral medication for Type 2 diabetes.

March 31, 2011
Study finds Januvia use could help prevent diabetes

A drug used to treat diabetes also may prevent it, according to a new study published in the journal Experimental Biology and Medicine.

CLEVELAND — A drug used to treat diabetes also may prevent it, according to a new study published in the journal Experimental Biology and Medicine.

Researchers at Case Western Reserve University took specially bred obese, prediabetic rats and gave them either Merck’s Januvia (sitagliptin), placebo or glyburide, an older diabetes drug. Both of the diabetes drugs lowered blood-glucose levels after the rats had eaten, but only Junuvia raised the total output of insulin by the pancreas while lowering levels of glucagon.

February 23, 2011
Onglyza gets label update

The makers behind a popular Type 2 diabetes treatment have included data from two clinical studies in an update to the drug's prescribing information.

PRINCETON, N.J., and WILMINGTON, Del. — The makers behind a popular Type 2 diabetes treatment have included data from two clinical studies in an update to the drug's prescribing information.

Bristol-Myers Squibb and AstraZeneca said the Food and Drug Administration approved the labeling update for Onglyza (saxagliptin), which now includes efficacy and safety information about the drug's effects on patients with renal impairment or end-stage renal disease.

January 11, 2011
FDA accepts application for extended-release Janumet

The Food and Drug Administration has accepted a regulatory approval application for a drug to treat Type 2 diabetes made by Merck, the drug maker said Tuesday.

WHITEHOUSE STATION, N.J. — The Food and Drug Administration has accepted a regulatory approval application for a drug to treat Type 2 diabetes made by Merck, the drug maker said Tuesday.

Merck announced the acceptance of its application for extended-release Janumet, which combines in a single pill the active ingredient sitagliptin with extended-release metformin, a drug commonly prescribed for Type 2 diabetes.

December 2, 2010
Decision Resources: Type 2 diabetes market in China to nearly double by 2014

A growing drug-treated population will cause the Type 2 diabetes drug market in China to increase to $2.5 billion by 2014 ...

BURLINGTON, Mass. — A growing drug-treated population will cause the Type 2 diabetes drug market in China to increase to $2.5 billion by 2014, according to a new report by Decision Resources.

The Type 2 diabetes market in China totaled $1.4 billion in 2009, Decision Resources said.

November 7, 2010
FDA approves Kombiglyze XR

The Food and Drug Administration approved the first and only once-a-day metformin extended-release plus dipeptidyl...

October 27, 2010
Decision Resources: More patients switch to Onglyza from Merck's Type 2 diabetes drugs

Many Type 2 diabetes patients who use the drug Onglyza (saxagliptin) switched to that drug...

BURLINGTON, Mass. Many Type 2 diabetes patients who use the drug Onglyza (saxagliptin) switched to that drug from Merck’s Januvia (sitagliptin) and Janumet (sitagliptin and metformin), according to a new report by market research firm Decision Resources.

 

March 16, 2010
FDA accepts NDA for combined diabetes drug

The Food and Drug Administration has accepted an approval application for a combination pill for...

January 5, 2010
Decision Resources: Onglyza sales will boast more than $1 billion

A research firm for pharmaceutical and healthcare issues projected sales of more than $1 billion...